Global Human Immunoglobulin (PH4) for intravenous Injection Market Size, Share and Trends Analysis Report, By Therapy (immunodeficiencies, Immunomodulatory And Anti-Inflammatory Therapy, And Hyperimmune Therapy), By Class ( IGM, IGG, IGD, IGA, AND IGE), Forecast (2022-2028)

The human immunoglobulin (PH4) for intravenous injection market is anticipated to grow at a significant CAGR of 12.7% during the forecast period (2022-2028). Immunoglobins or antibodies are mainly produced by plasma cells which are glycoprotein molecules. They work against various types of antigenic stimuli which are involved in the body to carry out physiological and pathological processes. When immunoglobulins are pooled and are derived from 1000 to 100000 healthy donors, they are known as Intravenous immunoglobulin (IVIG). They are a primary element in humoral adaptive immunity. This Intravenous immunoglobulin (IVIG) which are collected from a varied group of the population has different types of complexes mixed and can be beneficial against the varied type of infectious agents (bacterial, viral, and others), self-antigens, and anti-idiotype antibodies. IgG which is a class of   Immunoglobulins comprises around 90% of proteins when Intravenous immunoglobulin is prepared. For a successful therapeutic effect of this Intravenous immunoglobulin, it is mandatory that the protein content is high. Intravenous immunoglobulin therapy mainly aims to replenish Immunoglobulins antibodies. Furthermore, this in turn aims to neutralize varied types of infectious pathogens. Various immune cells which are present in the body are also activated through this therapy. Intravenous immunoglobulin has also been found effective in humoral primary immunodeficiencies.

 

The global human immunoglobulin (PH4) for intravenous injection market is segmented by therapy and by class. Based ontherapy, the market is sub-segmented into immunodeficiencies, immunomodulatory and anti-inflammatory therapy, and hyperimmune therapy. Based on class, the market is sub-segmented into igm, igg, igd, iga, and ige. Immunodeficiency disorders reduce the ability of the human body in fighting infections and diseases. Lymphocytes are white blood cells that are released in the body and they are classified as B and T cells. They help in fighting antigens or outside body cause infection. In the world, around 6 million people are affected by immunodeficiencies. Out of this population base, around 70-90 % of people remain undiagnosed.

 

Some major players in the market include Bayer AG, Pfizer Inc., Sanofi S.A., Novo Nordisk A/S, and Takeda Pharmaceutical Co., Ltd. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in May 2021, the Food and Drug Administration of the United States have accepted the license application of GC Pharma for GC5107 which will be effective in the treatment of Primary Humoral Immunodeficiency.

 

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Therapy
  • By Class
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Takeda Pharmaceutical Company Limited., Baxter International Inc., Bayer AG, ADMA Biologics, Inc.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Human immunoglobulin ph for intravenous injection Market Report by Segment

By Therapy

• Immunodeficiencies
• immunomodulatory and anti-inflammatory therapy
• hyperimmune therapy

By Class

• IgM
• IgG
• IgD
• IgA
• IgE

 

Human Immunoglobulin Ph For Intravenous Injection Market Report By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa